Shenzhen YHLO Biotech's high P/E ratio may not be justified ...

Shenzhen YHLO Biotech's high P/E ratio may not be justified by its growth outlook. Investors may face disappointment if the P/E falls to levels more in line with the growth outlook. The current high share price is seen as unreasonable given the predicted future earnings.